

## **The more symptoms the better? Covid-19 vaccine side effects and long-term neutralizing antibody response**

Ethan G. Dutcher<sup>1,2,\*</sup>, Elissa S. Epel<sup>1,2,\*</sup>, †, Ashley E. Mason<sup>1,3</sup>, Frederick M. Hecht<sup>3,4</sup>, James E. Robinson<sup>5</sup>,  
Stacy S. Drury<sup>4,5,6</sup>, Aric A. Prather<sup>1,2,\*</sup>, †

<sup>1</sup> Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA 94107

<sup>2</sup> Center for Health and Community, University of California, San Francisco, San Francisco, CA 94107

<sup>3</sup> Osher Center for Integrative Health, University of California, San Francisco, San Francisco, CA 94115

<sup>4</sup> Department of Medicine, University of California, San Francisco, San Francisco, CA 94115

<sup>5</sup> Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA 70112

<sup>6</sup> Department of Psychiatry, Tulane University School of Medicine, New Orleans, LA 70112

<sup>7</sup> Department of Psychiatry and Behavioral Sciences, Boston Children's Hospital, Brookline, MA 02445

\* Corresponding Authors: Ethan Dutcher, MD, PhD ([ethan.dutcher@ucsf.edu](mailto:ethan.dutcher@ucsf.edu)), Elissa Epel, PhD ([elissa.epel@ucsf.edu](mailto:elissa.epel@ucsf.edu)), Aric Prather, PhD ([aric.prather@ucsf.edu](mailto:aric.prather@ucsf.edu))

† Co-Senior Authors

### Abstract

Protection against SARS-CoV-2 wanes over time, and booster uptake has been low. This study explores the link between post-vaccination symptoms, biometric changes, and neutralizing antibodies (nAB) after mRNA vaccination. Data were collected from adults (n = 363) who received two doses of either BNT162b2 or mRNA-1273, with serum nAB concentration measured at 1 and 6 months post-vaccination. Daily symptom surveys were completed for six days starting on the day of each dose. Concurrently, objective biometric measurements, including skin temperature, heart rate, heart rate variability, and respiratory rate, were collected. We found that certain symptoms (chills, tiredness, feeling unwell, and headache) after the second dose were associated with increases in nAB at 1 and 6 months post-vaccination, to roughly 140-160% the level of individuals without each symptom. Each additional symptom predicted a 1.1-fold nAB increase. Greater changes in skin temperature and heart rate after the second dose predicted higher nAB levels. Skin temperature had a stronger predictive relationship for 6-month than 1-month nAB level. In the context of low ongoing vaccine uptake, our findings suggest that public health messaging could seek to reframe systemic symptoms after vaccination as desirable.

## Acknowledgements

The project was supported by funding from the National Institutes of Health (R24AG048024, 5U24AG066528, and U54CA260581).

## Author Contributions

JER, SSD, AEM, FMH, AAP, and ESE conceived of and designed the broader study; JER, AEM, AAP, and ESE collected the data; EGD, JER, and AAP accessed and verified the data; EGD designed and conducted the statistical analyses; EGD wrote the first draft of the manuscript; AAP and ESE provided critical feedback on the manuscript. All authors approved the final version for publication.

## Competing Interests

AEM has received remuneration from Oura Health for consulting. AAP is an advisor to NeuroGeneces and L-New Co. ESE is on the board of Meru Health and the Medical Advisory Board of Oura Health.

## **Introduction**

Vaccination against SARS-CoV-2 has been repeatedly shown to reduce infections, hospitalizations, and mortality, but protection wanes considerably over time for all of these outcomes, even following booster vaccination (1). Moreover, uptake of booster vaccinations has been low, with only 17% of the US population having received the bivalent booster as of May 2023, despite the vaccine having been widely available for over six months at that time (2). Among individuals who received at least one dose of a Covid-19 vaccine, the most commonly reported reasons for not having received a booster were (1) a perception of lack of benefit in protection from illness, given a personal history of prior SARS-CoV-2 infection or vaccination, and (2) worry about side effects (3, 4).

Recent evidence has suggested that greater systemic symptoms following SARS-CoV-2 vaccination may reflect a more potent immune response (5–7). A deeper understanding of this relationship may help to address low rates of vaccine uptake. If the effect is clinically meaningful, public health messaging might aid uptake by clearly reframing some post-vaccination symptoms as positive indications that the vaccine is likely to be working rather than negative side effects.

Although there are several reports suggesting that SARS-CoV-2 vaccine reactogenicity (i.e., resulting symptom burden or physiological perturbation) predicts higher subsequent anti-spike immunoglobulin level (5–7), only a small number of studies have specifically measured neutralizing antibodies (nAB), and results are inconsistent (8–10). Quantifying functional antibody activity (i.e., nAB) is important because although they are correlated, vaccine effects on nAB and absolute anti-spike IgG are dissociable, and nAB specifically appear critical in conferring protection from Covid-19. Only approximately 50% of the variability in nAB is predictable from anti-spike IgG (11), and nAB has been reported to have a larger effect size (i.e., lower hazard ratio per 10-fold increase) than anti-spike IgG in predicting subsequent Covid-19 incidence (12). It has been demonstrated that providing animals with neutralizing antibodies alone confers protection from against disease even after high-dose SARS-CoV-2 exposure (13), and in one study in humans, nAB level was estimated to mediate over two-thirds of vaccine efficacy (12). A recent meta-analysis (14) and large pooled cohort analysis (15) have estimated the rank correlation between nAB level and protection against symptomatic infection to be 0.81 and 0.91 respectively.

Using data from a cohort of adults who received the initial two-dose series of BNT126b2 or mRNA-1273, we used convergent self-report symptom and objective biometric measures to examine the association between physiological perturbation following vaccination and subsequent nAB concentration in serum at 1 and 6 months after full vaccination. We examined symptom predictors for each dose that included the presence or absence of 13 individual symptoms and total symptom burden. Objective measures we assessed included vaccination-induced change in skin temperature, heart rate, heart rate variability, and respiratory rate, which were measured during sleep using a wearable device (the Oura ring).

## **Results**

### **Symptom predictors of neutralizing antibodies**

Each symptom was examined as a predictor of subsequent nAB using separate multivariable models. Following correction for multiple comparisons, no statistically significant effects of symptom presence or absence at dose one were identified. For dose two, no interactions were significant, while main effects were significant for four of 13 symptoms (Figure 1): chills ( $F_{1,338.0} = 17.78$ ,  $p = 0.001$ ), tiredness ( $F_{1,339.3} = 14.38$ ,  $p = 0.004$ ), feeling unwell ( $F_{1,338.7} = 15.75$ ,  $p = 0.003$ ), and headache ( $F_{1,338.9} = 14.56$ ,  $p = 0.004$ ). nAB were higher for subjects reporting vs. not reporting the following symptoms at dose two: chills (1.6 fold higher; increase in log<sub>10</sub> ID<sub>50</sub> = 0.21, CI 0.12 to 0.30), tiredness (1.5 fold higher; increase in log<sub>10</sub> ID<sub>50</sub> = 0.17, CI 0.069 to 0.26), feeling unwell (1.5 fold higher; increase in log<sub>10</sub> ID<sub>50</sub> = 0.17, CI 0.088 to 0.25), and headache (1.4 fold higher; increase in log<sub>10</sub> ID<sub>50</sub> = 0.15, CI 0.075 to 0.24). Because symptom presence did not interact with outcome time point or vaccine for any symptom, all results are presented without regard to outcome time point and vaccine. Specifically, results represent differences in marginal means (also known as least-squares means); i.e., values represent the average effect of each symptom across both vaccines and both time points, weighting these according to their representation in the sample.

### **Symptom count as a predictor of neutralizing antibodies**

Symptom count was intended as a continuous index of systemic symptom burden, so injection site symptoms were excluded from counting. For dose one, there were no main or interaction effects involving symptom count. For dose two, no interactions were significant, but there was a main effect of symptom count ( $F_{1,337.9} = 24.50$ ,  $p < 0.001$ ; Figure 2), involving a 1.1 fold change in nAB (ID<sub>50</sub>) per additional symptom (change in log<sub>10</sub> ID<sub>50</sub> per additional symptom: 0.042, CI 0.026 to 0.058; partial correlation,  $r_p = 0.27$ , CI 0.17 to 0.36).

### **Biometric predictors of neutralizing antibodies**

For vaccination-induced change in nightly 99<sup>th</sup> percentile at dose one, there were no significant main or interaction effects. However, at dose two, there was a significant interaction between outcome time point and vaccination-induced change in nightly 99<sup>th</sup> percentile skin temperature ( $F_{1,127.5} = 13.96$ ,  $p = 0.005$ ; Figure 3, top right). Post-hoc testing revealed that vaccination-induced change in nightly skin temperature was predictive of nAB at 1-month follow-up (fold change in ID<sub>50</sub> per degree Celsius: 1.8; change in log<sub>10</sub> ID<sub>50</sub> per degree Celsius: 0.26, CI 0.13 to 0.40,  $p < 0.001$ ;  $r_p = 0.27$ , CI 0.13 to 0.39) and at 6-month follow-up (fold change in ID<sub>50</sub> per degree Celsius: 3.1; change in log<sub>10</sub> ID<sub>50</sub> per degree Celsius: 0.50, CI 0.35 to 0.64,  $p < 0.001$ ;  $r_p = 0.45$ , CI 0.33 to 0.55), with the steeper relationship for the 6-month follow-up being responsible for the interaction.

For vaccination-induced change in nightly 1<sup>st</sup> percentile heart rate at dose one, there were no significant main or interaction effects. However, at dose two, a main effect of vaccination-induced change in nightly 1<sup>st</sup> percentile heart rate was observed ( $F_{1,132.0} = 10.20$ ,  $p = 0.029$ ; Figure 3, bottom right), in the absence of any interaction with outcome time point or vaccine. Averaged across the levels of these and other categorical predictors, nAB levels increased by 1.5 fold for every 10 beats per minute deviation from a subject's norm (increase in log<sub>10</sub> ID<sub>50</sub> per additional 10 beats per minute: 0.19, CI 0.071 to 0.31;  $r_p = 0.27$ , CI 0.10 to 0.41).

Neither vaccination-induced change in nightly 99<sup>th</sup> percentile HRV nor in average nightly RR was significantly predictive of subsequent nAB via either main or interaction effects, for either vaccine dose.

## **Discussion**

We show here that individuals who reported experiencing chills, tiredness, feeling unwell, or headache following the second dose of a SARS-CoV-2 vaccine subsequently had 140-160% of the neutralizing antibody level of people who did not report these symptoms, at both 1 and 6 months later. We also show that each additional symptom experienced following dose two predicted a 1.1 fold increase in subsequent nAB. This means that, on average, individuals reporting 7 distinct symptoms subsequently had nearly 200% the nAB level of individuals reporting 0 symptoms. Using objective biometric data, we present convergent findings showing that greater vaccination-induced change in body temperature and heart rate, specifically at dose two, predicts greater nAB, especially at 6-month follow-up. Effect sizes were again large, with a difference between individuals of 1 degree Celsius in vaccination-induced change in skin temperature predicting 300% of the nAB level six months later.

Several prior publications have examined the association between systemic symptoms following receipt of a SARS-CoV-2 mRNA vaccine and subsequent nAB level, with inconsistent results. In one report, at dose two of mRNA-1273 ( $n = 171$ ), none of three local or eight systemic symptoms, nor the presence of any local or any systemic symptom, predicted nAB 4 weeks later (8). By contrast, there are two reports of a positive association between systemic symptoms and nAB. In one study in 163 subjects, it was reported that for both dose one and two, the presence of at least one systemic symptom predicted higher nAB at 12-19 days after dose two (10). In the other report, the presence of at least one systemic symptom at dose three predicted higher nAB at a median of 54 days later (9).

One key methodological distinction that may drive these discrepant results is that the first study did not include any BNT162b2 recipients (8), whereas our study and the other two studies used samples consisting of at least 50% BNT162b2 recipients. We have previously shown that increasing age predicted lower subsequent nAB for BNT162b2 recipients but not mRNA-1273 recipients (16). This may have resulted from the fact that the initial formulation of mRNA-1273 contained over three times the mRNA dose of the initial BNT162b2 formulation (17), and resulted in a humoral immune response that was stronger to such an extent that there was lower variability between subjects, suggesting a ceiling effect (16). It may be that the lower variability between mRNA-1273 recipients in antibody outcomes, and perhaps side effect outcomes, compromises statistical power to detect relationships with side effects, particularly when outcomes are measured shortly after completion of the initial series. Indeed, in the present study, we show several predictive relationships that are stronger or only significant for predicting the 6-month rather than 1-month outcome. There are a few other reports examining the association between reactogenicity to SARS-CoV-2 vaccination and subsequent nAB, but interpretability is limited due to low samples sizes (4 to 8 per condition) (18), the analysis only of nAB trajectories over time (19), which are confounded by absolute levels given that higher decay rates correlate with higher initial levels (11), and the use of a mixed sample of mRNA and adenoviral vector vaccine recipients (20).

There are several key strengths of our study compared to the previous large studies (8–10). Firstly, neither of the two studies that included BNT162b2 recipients examined individual symptoms as predictors of nAB. Here, we show that it is specifically chills, tiredness (or fatigue), generally feeling unwell, and headache that drive the predictive relationship between systemic symptoms and nAB. Secondly, these studies all measured nAB within 2 months of receipt of the second dose of an mRNA vaccine, whereas we report on measurements as late as 6 months. This long follow-up is important and relevant given that individuals are unlikely to receive booster vaccination before 6 months or even a year following the initial series. We show that most predictive relationships apply equally for nAB at both 1 month and 6 months

following the initial series, but certain biomarker measurements (change in skin temperature and change in heart rate) were more informative for predicting long-term than short-term nAB. Third, in addition to self-report measures that may be vulnerable to psychological or cognitive influences, for example variability in the tendency to notice, emphasize, remember, or report adverse effects, we use objective biometric measurements of physiological perturbation that is not vulnerable to these influences. Using this data, we present findings that neatly concord with our self-report data. Only one prior study has used non-self-report objective biometric data to predict subsequent humoral immune response after SARS-CoV-2 vaccination (21). That study found positive associations between vaccination-induced change in skin temperature and heart rate and subsequent anti-spike immunoglobulin at roughly 1 month later, in a mixed mRNA and adenoviral vector vaccine sample. Here, we extend those findings, demonstrating similar relationships with nAB at 6 months later, in an mRNA vaccine sample. Finally, our study is the first study of reactogenicity and nAB level following mRNA vaccination conducted in the US, enhancing generalizability to that context, and one of the first such studies to be conducted in a general population rather than convenience sample of healthcare workers.

There are several limitations to our study. Firstly, our results are from individuals who received only the initial Covid-19 vaccine series. Estimates based on survey data indicate that as of March 2023, roughly 24% of US adults are unvaccinated, 25% received the initial series but no booster doses, 25% received one booster dose, and 23% received the bivalent booster dose (22). The CDC estimated bivalent booster uptake slightly lower, at 17% as of May 2023 (2). It is not clear whether the relationships observed here would apply to individuals undergoing initial vaccination using the updated vaccine formulations. Secondly, our results are from individuals who did not have any serological evidence of SARS-CoV-2 infection. It is unknown whether in individuals with a prior history of SARS-CoV-2 infection, the same predictive ability of symptoms and vaccination-induced change in biometrics would be observed. However, among individuals receiving a two-dose mRNA vaccination, those with a prior history of SARS-CoV-2 infection have been reported to have both greater subsequent anti-spike IgG concentrations (23) and greater reactogenicity (24), suggesting that a predictive association between neutralizing antibodies and reactogenicity may be likely. A third limitation is that our pseudovirus assay used the spike protein from the original Wuhan/D614G strain of SARS-CoV-2, which may limit generalizability of the findings, especially given that omicron variants have comprised virtually all circulating SARS-CoV-2 virus in the US since February 2022 through September 2023 (25). Finally, we only address humoral immunity in this study, and although evidence suggests that neutralizing antibodies mediate roughly two-thirds of vaccine efficacy (12), cellular immunity is believed to play an important role in protection from severe disease (26, 27).

In sum, we show here in a large community sample that systemic symptoms and increases in skin temperature and heart rate following SARS-CoV-2 mRNA vaccination predict higher subsequent nAB level. We show that these relationships are stronger when predicting longer-term rather than short-term nAB outcome. Our results suggest that the presence or absence of symptoms might be able to be used as an approximate proxy for likely protection against Covid-19, by individuals or their healthcare providers. In the context of low rates of booster uptake, our findings have particular relevance for individuals with a degree of ambivalence regarding receiving a booster vaccination.

## **Methods**

### **Subjects**

Subjects were participants in the Building Optimal Antibodies Study (16), a large observational study aimed at identifying factors such as psychosocial, behavioral, and biological predictors of immune responses to COVID-19 vaccination. Participants were adults aged 18 years and above who did not have a previous history of immune-related diseases and were not currently undergoing treatment with medications known to impact the immune system. Ethical approval was provided by the Institutional Review Board at the University of California, San Francisco, and all study participants provided written informed consent.

Serum was collected from study participants before they received a COVID-19 vaccine and again 1 and 6 months after they completed their initial two-dose series of BNT162b2 or mRNA-1273. Participants independently arranged to be vaccinated in the community, and vaccination date and type was later determined using official records. History of SARS-CoV-2 infection was examined by measuring levels of anti-spike IgG antibodies at baseline and anti-nucleocapsid IgG antibodies at 6 months. Participants with a positive result on either test were excluded from analyses. Participants were also excluded if they received a third vaccine dose before the 6-month follow-up, or if no outcome measurement was available. Sample characteristics are provided in Table 1.

### **Outcome**

Neutralizing antibodies against SARS-CoV-2 were measured via pseudovirus assay at 1 and 6 months following vaccination as described previously (16). In brief, serum from each participant was serially diluted and mixed with pseudovirus expressing full-length SARS-CoV-2 protein, facilitating binding and neutralization by host antibodies. Incubation with susceptible cells allowed remaining functional pseudovirus to deliver luciferase intracellularly, resulting in fluorescence. The titer that resulted in a 50% reduction in fluorescence compared to serum-free controls (i.e., the inhibitory dose 50, ID50) was taken as a measure of the neutralizing antibody concentration. The ID50 was then log<sub>10</sub>-transformed for analysis.

### **Daily symptom surveys**

Subjects were sent links to surveys each evening for six days, beginning on the date they anticipated receiving each dose of a SARS-CoV-2 vaccine. The survey included the question, “Did you experience any of the following physical symptoms today? (Check all that apply.)”. The following options were provided, in order: Tiredness; Headache; Muscle pain; Chills; Joint pain; Fever; Nausea / vomiting; Feeling unwell; Tender or swollen lymph nodes (lymphadenopathy); Injection site pain, redness or swelling; Pain or swelling in the arm that did not get the vaccination; Other allergic reactions (difficulty breathing, swelling of face/throat, rash); Stomachache; None of the above. For each survey entry, vaccine dose dates were used to calculate calendar days since receipt of either dose one or two. For each symptom (or group of symptoms), data were collapsed to reflect either presence on any of the six days or absence on all six days.

### **Biometric collection and analysis**

Heart rate (HR), heart rate variability (HRV), respiratory rate (RR), and skin temperature (ST) data were collected from a subset of participants using a biometric wearable device, the Oura ring. Data were

exported from the web application Oura Teams in March 2022. Oura software detects and classifies sleep into sleep periods according to a proprietary algorithm. HR and HRV were exported for each 5-minute interval of the longest sleep period per 24 hours. HRV was provided in the form of the root mean square of successive differences (RMSSD) (28). Skin temperature was recorded for every 1 minute that the device was worn; these data were filtered to only those recordings that occurred during sleep (29).

To test the hypotheses that short-term effects of vaccination on nighttime HR, HRV, RR, and ST are predictive of subsequent neutralizing antibody response, it was necessary to derive summary values of vaccination-induced change in each of these physiological domains for each subject. For this purpose, for each domain, we used a multi-step procedure to identify the summarization approach that best indexed vaccination-induced change (30, 31); see the Supplementary Information for details. Ultimately, nightly time series were first summarized into single nightly values for each subject for ST and HRV by taking the 99<sup>th</sup> percentile (i.e., the “stable maximum”), and for HR by taking the 1<sup>st</sup> percentile (i.e., the “stable minimum”); RR was only available in the form of a nightly average. Then, one summary value was derived for each subject for each physiological domain at each vaccine dose, by taking the peak deviation (maximum for HR, RR, and ST; minimum for HRV) from each subject’s individualized norm (or “baseline”) over the first two nights following receipt of a given vaccine dose.


## Data analysis

Data processing, graphing, and statistical analysis were performed in R v4.2.2. For all analyses, mixed-effects models were fit to nAB data collected at 1 month and 6 months following completion of the initial vaccine series. All models included a core set of terms, including a time point  $\times$  vaccine interaction and main effects of age, sex, and BMI. The statistical significance of these terms has been previously described (16). Here, for each vaccine dose, 18 variables were examined as predictors of subsequent nAB level: the presence or absence of 13 symptom categories, the total count of reported symptom categories (excluding injection site symptoms), and the levels of 4 biometric measurements. For each variable, a model was created by adding to the core model structure the following terms: a main effect, an interaction with vaccine, an interaction with time point, and the three-way interaction between these variables. Thus, four hypotheses of interest were tested in each model, with the exception of five models where one or more interaction terms were removed to resolve multicollinearity (see Supplementary Information for more detail or Table S3 for the full list of tested hypotheses and associated statistics). Predictor significance was tested using F statistics. Ultimately, 130 p-values (1 to 4 per model) were drawn from 36 models; these were consolidated and corrected for multiple comparisons using the Benjamini-Hochberg method. Statistical significance was defined as corrected  $p < 0.05$ ; significant F-statistics were followed by post-hoc t-tests without further correction. All presented results represent marginal effects, i.e., effects adjusted for the other terms in the model. Thus, where results are presented without respect to outcome time point, these represent effects averaged across both time points. For statistically significant continuous predictors, the partial correlation ( $r_p$ ) was provided alongside absolute effect sizes. Visualizations represent marginal means  $\pm$  95% confidence intervals (CI) along with partial residuals. Detailed information can be found in the Supplementary Information.




	Symptom analyses (n = 363)	Biometric analyses (n = 147)
Age, mean (SD)	52.4 (11.9)	58.8 (5.3)
BMI, mean (SD)	26.9 (5.9)	27.4 (6.4)
Female, n (%)	238 (65.6)	97 (66.0)
Smoked at baseline, n (%)	6 (1.7)	3 (2.0)
Vaccine, BNT162b2, n (%)	235 (64.7)	94 (63.9)
Race/ethnicity, n (%)		
Asian	84 (23.1)	26 (17.7)
Black/African American	6 (1.7)	4 (2.7)
Hispanic/Latinx	33 (9.1)	7 (4.8)
Other/Multiracial	26 (7.2)	6 (4.1)
White	213 (58.7)	103 (70.1)
Education level, n (%)		
4-year degree	129 (35.5)	51 (34.7)
Professional degree or doctorate	178 (49.0)	76 (51.7)
Some college or less	56 (15.4)	20 (13.6)
Household income, n (%)		
Less than \$50,000	37 (10.2)	17 (11.6)
\$50,000 to less than \$100,000	69 (19.0)	28 (19.0)
\$100,000 to less than \$200,000	108 (29.8)	48 (32.7)
\$200,000 or more	94 (25.9)	35 (23.8)
Prefer not to answer	55 (15.2)	19 (12.9)
Marital status, n (%)		
Married or with a long-term partner	213 (58.7)	91 (61.9)
Never married	108 (29.8)	36 (24.5)
Divorced or separated	35 (9.6)	16 (10.9)
Widowed	7 (1.9)	4 (2.7)

**Table 1. Sample characteristics.** Demographic characteristics are provided for subjects included in at least one symptom analysis (left) or biometric analysis (right).




**Figure 1. Association between symptoms following the second vaccine dose and subsequent neutralizing antibody responses.** Participants completed daily surveys on the day of and five days following each vaccination dose, reporting the presence or absence of specific symptoms each day. For each symptom (or group of symptoms), data were collapsed to reflect either presence on any of the six days or absence on all six days. Neutralizing antibodies were measured at 1 month and 6 months following completion of the initial vaccine series. Each symptom at each dose was individually tested as a potential predictor of neutralizing antibody levels at both outcome time points simultaneously, in multivariable mixed-effects models that controlled for other baseline variables. After correcting for multiple comparisons, four symptoms remained statistically significant predictors of neutralizing antibodies, although only when measured at dose two: chills, tiredness, feeling unwell, and headache. Injection site symptoms are included in the figure for comparison. Blue lines represent the marginal

means +/- 95% confidence intervals. There was no interaction between the effect of each symptom and vaccine or time, nor was the three-way interaction between these variables significant. Therefore, marginal means are not stratified by time or vaccine, and instead represent the average effect over these variables.



**Figure 2. Association between total number of unique symptoms following first vaccine dose (left, for all three vaccines) or second vaccine dose (right, for BNT162b2 and mRNA-1273) and subsequent neutralizing antibody levels.** Symptom count at second dose was a statistically significant predictor of subsequent neutralizing antibody level ( $p < 0.001$ ). Neither symptom count interacted with vaccine brand or measurement time point (1 month and 6 months following initial series completion); therefore, results represent the average relationship across both time points and all applicable vaccines (i.e., marginal means  $\pm$  95% confidence intervals).



**Figure 3. Association between vaccination-induced change in three physiological domains and subsequent neutralizing antibody levels.** A subset of study participants wore biometric devices (Oura rings) that collected physiological measurements during sleep. Data were available as nightly time series. The nightly stable maximum (99th percentile) was identified to be most sensitive to vaccination-induced change for ST, while the nightly stable minimum (1st percentile) was most sensitive to vaccination-induced change for HR. Once the most sensitive index of vaccination-induced deviation was identified for each physiological domain, these indices were then tested as potential predictors of subsequent

neutralizing antibody responses at 1 month and 6 months simultaneously. Plots depict the relationship between vaccination-induced change in nightly stable-maximum ST (top row) and nightly stable-minimum HR (bottom row) and subsequent neutralizing antibody level at 1 month and 6 months following completion of the initial two-dose series of BNT162b2 and mRNA-1273. Vaccination-induced change in stable-maximum ST at dose two predicted subsequent neutralizing antibody (nAB) level at both 1 month and 6 months later (top right). There was a main effect of vaccination-induced change in stable-minimum HR on subsequent nAB level (bottom right).

## **Supplementary methods**

### **Biometric data processing**

For each nightly sleep period, a time series of measurements was available for three physiological domains (HR, HRV, and ST), while RR was provided as an average across the sleep period. For each of these three domains, three candidate methods of summarizing each set of nightly measurements into one nightly summary value were considered, i.e., taking the 1<sup>st</sup> percentile, the mean, and the 99<sup>th</sup> percentile. For a given sleep period and domain, these nightly summary values were only calculated where the domain was successfully recorded for the whole sleep period.

For each of the 10 nightly summary variables (3 for HR, 3 for HRV, 3 for ST, and 1 for RR), a subject norm was calculated for each subject by averaging over the available measurements across a 10-night period from nights 7 through 16 after dose one. The start of this window was chosen because vaccination side effects have generally resolved by this time (24, 32), and no subjects received a second dose by night 16. Nightly summary variables were then centered on each subject norm.

Nightly statistics were then collapsed across nights to generate per-subject summary statistics of vaccination-induced change. For nights 0 and 1 following each dose, the nightly mean HR and ST was positive on average, while for HRV it was negative on average, indicating that the direction of any effect of vaccination on HR, RR, and ST was an increase, while for HRV it was a decrease. Because subjects received vaccination at varying times of day, between-subject variability in the time to maximal vaccination-induced change was anticipated. Across nights 0 through 3 following each dose, the majority of subjects experienced their peak deviation from baseline (maximum for mean nightly HR, RR, and ST; minimum for mean nightly HRV) on either night 0 or 1, so the larger deviation over these two nights was taken as each subject's vaccination-induced change in each of the ten variables, for each vaccine dose.

The nightly summary method (i.e., 1<sup>st</sup> percentile, mean, or 99<sup>th</sup> percentile) most sensitive to vaccination-induced change in each of HR, HRV, and ST was then identified by using one sample t-tests to compare the dose two summary variables derived from the nightly 1<sup>st</sup> percentile, mean, and 99<sup>th</sup> percentile values. Dose two was used for the purpose of variable selection because side effects are more common at dose two and therefore variable comparison was less likely to be influenced by random variability (Rosenblum et al., 2022). The most sensitive variable was defined as the one with the lowest p-value. The nightly 99<sup>th</sup> percentile was identified as most sensitive to vaccination-induced change for HRV and ST, while the nightly 1<sup>st</sup> percentile was most sensitive to vaccination-induced change for HR.

### **Data analysis**

Linear mixed-effects models were fit using *lme4* using restricted maximum likelihood estimation. Deviation (sum-to-zero) coding was used for categorical predictors. Continuous predictors were mean centered prior to model fitting. Random effects included a random intercept per subject. All models were checked for multicollinearity by examination of variance inflation factors (VIFs) calculated using *car*. The VIF threshold of 5 was exceeded in the initial model for each of the following predictors of interest: other allergic reactions (dose one), pain or swelling in the non-injected arm (dose one), tender or swollen lymph nodes (dose one), fever (dose one), other allergic reactions (dose two). In all cases, multicollinearity was the result of low variability in these predictors, resulting in the higher-order two- or three-way interaction terms being correlated with vaccine, time point, or both. This was resolved by removing all interaction terms involving each predictor of interest. All final models met assumptions of

residual normality, linearity, and equality of variance, as assessed via diagnostic plots. No single observation had an undue influence on model fit, given that all had a Cook's distance below 1.

Significance of model terms was evaluated via F statistics calculated using Type II sums of squares, meaning that the F statistic corresponding to a given term compared the predictions of the full model including that term but without any higher-order interaction terms to the same model without the given term (33). Degrees of freedom were approximated via the Kenward-Roger method.

Results are provided as either marginal means (i.e., least-squares means), fold difference in marginal means, marginal slopes, or the difference between a pair of marginal means or slopes, all calculated using *emmeans*. All such estimates assumed (i.e., were conditioned on) mean levels of continuous covariates (age, BMI, baseline anti-spike IgG), and were averaged across the estimates for each level of other categorical predictors (vaccine, gender, time point, smoking status), weighting each level of these variables proportional to its representation in the sample. Post-hoc testing was performed on these estimates, comparing two using a two-sample t-test, or comparing marginal slopes (simple slopes) to zero using a one-sample t-test. Marginal means were provided in the untransformed (ID50) scale, and fold differences were calculated in this scale. Marginal trends and pairwise contrasts refer to effects on the outcome in the log<sub>10</sub> scale.

The *effectsize* package was used to convert t or Type II sums of squares F statistics and associated degrees of freedom to standardized effect sizes, specifically the partial correlation ( $r_p$ ) or partial  $\eta^2$ .

All visualizations were produced with *ggeffects* for calculation of partial residuals, along with *ggplot2* and *patchwork*.



### **Supplementary tables**

<b>Symptom or symptom category</b>	<b>Dose one frequency (%); n = 354</b>	<b>Dose two frequency (%); n = 347</b>
Injection site pain, redness or swelling	256 (72.3)	251 (72.3)
Tiredness	192 (54.2)	262 (75.5)
Muscle pain	112 (31.6)	190 (54.8)
Headache	96 (27.1)	184 (53.0)
Feeling unwell	65 (18.4)	140 (40.3)
Joint pain	29 (8.2)	94 (27.1)
Stomachache	27 (7.6)	40 (11.5)
Chills	24 (6.8)	104 (30.0)
Nausea or vomiting	17 (4.8)	42 (12.1)
Fever	16 (4.5)	75 (21.6)
Tender or swollen lymph nodes	13 (3.7)	32 (9.2)
Pain or swelling in non-injected arm	10 (2.8)	29 (8.4)
Other reactions (difficulty breathing, swelling of face/throat, rash)	9 (2.5)	7 (2.0)

**Table S1. Descriptive statistics for symptoms and symptom categories.** Numbers and proportions of subjects reporting each of 13 symptoms are presented, for dose one and dose two.

<b>Vaccination-induced change in:</b>	<b>Dose one mean (SD); n = 162</b>	<b>Dose two mean (SD); n = 145</b>	<b>One-sample t-statistic for dose two</b>	<b>p value</b>
HR: nightly 99th percentile	2.81 (4.95)	6.19 (7.72)	9.51	7e-17
HR: nightly mean	2.12 (3.74)	5.48 (6.89)	9.45	1e-16
HR: nightly 1st percentile	1.82 (3.27)	4.76 (6.04)	9.36	2e-16
HRV: nightly 99th percentile	-9.05 (13.62)	-10.63 (15.19)	-8.30	8e-14
HRV: nightly mean	-4.44 (8.12)	-5.6 (8.62)	-7.72	2e-12
HRV: nightly 1st percentile	-2.74 (5.74)	-3.11 (5.96)	-6.20	6e-09
ST: nightly 99th percentile	0.21 (0.23)	0.63 (0.63)	11.67	5e-22
ST: nightly mean	0.27 (0.39)	0.48 (0.5)	11.09	1e-20
ST: nightly 1st percentile	0.71 (1.92)	0.76 (1.88)	4.69	7e-06
RR: nightly mean	0.3 (0.56)	0.94 (1.01)	11.00	1e-20

**Table S2. Descriptive statistics for biometric data.** Biometric data at the time of either vaccine dose was available for a total of 168 subjects, with 162 providing data at dose one and 145 providing data at dose two. Respiratory rate (RR; breaths per minute) was available only as a nightly average. For heart rate (HR; beats per minute), heart rate variability (HRV; root mean square of successive differences, in milliseconds), and skin temperature (ST; degrees Celsius), one-sample t-tests were used to identify the approach to summarizing the nightly time series that was most sensitive to vaccination-induced change. For HRV and ST, this was the 99<sup>th</sup> percentile, and for HR, it was the 1<sup>st</sup> percentile. These summary approaches were then used to test hypotheses regarding the ability of vaccination-induced change in each physiological domain to predict subsequent neutralizing antibody level.

Predictor	Partial $\eta^2$	F	Df	p (uncorr.)	p	
Change in max. nightly skin temp. (D2)	0.21 (0.1 to 0.33)	32.93	1,126.1	7e-08	8e-06	***
Symptom count (D2)	0.07 (0.03 to 0.13)	26.35	1,338.6	5e-07	3e-05	***
Chills (D2)	0.06 (0.02 to 0.11)	20.65	1,339.2	8e-06	3e-04	***
Headache (D2)	0.05 (0.01 to 0.1)	16.81	1,340.2	5e-05	0.002	**
Feeling unwell (D2)	0.05 (0.01 to 0.1)	16.44	1,339.4	6e-05	0.002	**
Tiredness (D2)	0.04 (0.01 to 0.09)	15.24	1,340.1	1e-04	0.002	**
Time point $\times$ Change in max. nightly skin temp. (D2)	0.1 (0.02 to 0.21)	13.98	1,127.5	3e-04	0.005	**
Change in min. nightly HR (D2)	0.07 (0.01 to 0.17)	10.19	1,133	0.002	0.028	*
Time point $\times$ Change in avg. nightly RR (D1)	0.06 (0.01 to 0.15)	8.60	1,134.4	0.004	0.055	
Tiredness (D1)	0.02 (0 to 0.06)	8.14	1,346.6	0.005	0.058	
Time point $\times$ Change in avg. nightly RR (D2)	0.06 (0.01 to 0.15)	8.09	1,134.6	0.005	0.059	
Time point $\times$ Change in min. nightly HR (D2)	0.05 (0 to 0.14)	7.61	1,134.2	0.007	0.069	
Change in avg. nightly RR (D2)	0.05 (0 to 0.14)	7.32	1,133.3	0.008	0.075	
Vaccine $\times$ Time point $\times$ Change in min. nightly HR (D1)	0.05 (0 to 0.14)	7.18	1,134.3	0.008	0.075	
Muscle pain (D2)	0.02 (0 to 0.06)	6.74	1,338.8	0.010	0.083	
Joint pain (D2)	0.02 (0 to 0.06)	6.60	1,339.4	0.011	0.083	
Fever (D2)	0.02 (0 to 0.06)	6.46	1,338.1	0.011	0.085	
Time point $\times$ Change in max. nightly skin temp. (D1)	0.05 (0 to 0.14)	6.40	1,127.2	0.013	0.089	
Tender or swollen lymph nodes (D2)	0.02 (0 to 0.05)	5.87	1,343.6	0.016	0.11	
Symptom count (D1)	0.01 (0 to 0.05)	5.01	1,345.6	0.026	0.16	
Vaccine $\times$ Change in max. nightly skin temp. (D2)	0.03 (0 to 0.11)	4.31	1,126.3	0.040	0.24	
Vaccine $\times$ Feeling unwell (D1)	0.01 (0 to 0.04)	3.85	1,348.6	0.051	0.29	
Vaccine $\times$ Tender or swollen lymph nodes (D2)	0.01 (0 to 0.04)	3.78	1,345.2	0.053	0.29	
Tender or swollen lymph nodes (D1)	0.01 (0 to 0.04)	3.61	1,345.7	0.058	0.31	
Other allergic reactions (difficulty breathing, swelling of face/throat, rash) (D1)	0.01 (0 to 0.04)	3.36	1,345.8	0.068	0.34	
Vaccine $\times$ Pain or swelling in non-injected arm (D2)	0.01 (0 to 0.04)	3.13	1,344.7	0.078	0.38	
Vaccine $\times$ Joint pain (D2)	0.01 (0 to 0.04)	2.98	1,339.2	0.085	0.38	
Time point $\times$ Joint pain (D2)	0.01 (0 to 0.04)	2.94	1,337.4	0.088	0.38	
Vaccine $\times$ Symptom count (D2)	0.01 (0 to 0.04)	2.90	1,338.3	0.090	0.38	
Vaccine $\times$ Joint pain (D1)	0.01 (0 to 0.04)	2.89	1,356.8	0.090	0.38	
Vaccine $\times$ Time point $\times$ Pain or swelling in non-injected arm (D2)	0.01 (0 to 0.04)	2.84	1,343	0.093	0.38	
Vaccine $\times$ Feeling unwell (D2)	0.01 (0 to 0.04)	2.73	1,339.9	0.100	0.39	
Vaccine $\times$ Time point $\times$ Muscle pain (D1)	0.01 (0 to 0.04)	2.53	1,345.3	0.11	0.43	
Injection site pain, redness or swelling (D2)	0.01 (0 to 0.03)	2.32	1,338.4	0.13	0.48	
Headache (D1)	0.01 (0 to 0.03)	2.13	1,346.4	0.15	0.52	
Time point $\times$ Muscle pain (D1)	0.01 (0 to 0.03)	1.84	1,345.2	0.18	0.55	
Time point $\times$ Feeling unwell (D2)	0.01 (0 to 0.03)	1.83	1,337.8	0.18	0.55	
Vaccine $\times$ Chills (D2)	0.01 (0 to 0.03)	1.82	1,339.3	0.18	0.55	
Vaccine $\times$ Time point $\times$ Injection site pain, redness or swelling (D2)	0.01 (0 to 0.03)	1.79	1,336.4	0.18	0.55	
Vaccine $\times$ Time point $\times$ Stomachache (D1)	0.01 (0 to 0.03)	1.79	1,344.4	0.18	0.55	
Vaccine $\times$ Time point $\times$ Joint pain (D2)	0.01 (0 to 0.03)	1.78	1,337.9	0.18	0.55	
Vaccine $\times$ Change in max. nightly HRV (D1)	0.01 (0 to 0.08)	1.78	1,133	0.18	0.55	
Vaccine $\times$ Time point $\times$ Change in max. nightly HRV (D1)	0.01 (0 to 0.07)	1.74	1,134.1	0.19	0.55	
Time point $\times$ Stomachache (D2)	0 (0 to 0.03)	1.64	1,335.8	0.20	0.58	
Vaccine $\times$ Fever (D2)	0 (0 to 0.03)	1.59	1,338.2	0.21	0.58	
Time point $\times$ Joint pain (D1)	0 (0 to 0.03)	1.49	1,351.5	0.22	0.60	
Vaccine $\times$ Symptom count (D1)	0 (0 to 0.03)	1.47	1,345.5	0.23	0.60	
Muscle pain (D1)	0 (0 to 0.03)	1.46	1,345.5	0.23	0.60	
Vaccine $\times$ Time point $\times$ Change in max. nightly HRV (D2)	0.01 (0 to 0.07)	1.30	1,134.1	0.26	0.66	
Vaccine $\times$ Chills (D1)	0 (0 to 0.03)	1.16	1,344.9	0.28	0.70	

Vaccine × Change in max. nightly skin temp. (D1)	0.01 (0 to 0.07)	1.17	1,125.5	0.28	0.70	
Vaccine × Time point × Muscle pain (D2)	0 (0 to 0.03)	1.13	1,337.7	0.29	0.70	
Change in max. nightly skin temp. (D1)	0.01 (0 to 0.07)	1.08	1,126.2	0.30	0.71	
Vaccine × Change in min. nightly HR (D1)	0.01 (0 to 0.06)	1.05	1,133.4	0.31	0.72	
Chills (D1)	0 (0 to 0.02)	0.97	1,344.8	0.33	0.74	
Time point × Symptom count (D2)	0 (0 to 0.02)	0.95	1,337.1	0.33	0.74	
Time point × Muscle pain (D2)	0 (0 to 0.02)	0.94	1,337.3	0.33	0.74	
Time point × Chills (D2)	0 (0 to 0.02)	0.84	1,337.8	0.36	0.76	
Time point × Headache (D2)	0 (0 to 0.02)	0.83	1,338.5	0.36	0.76	
Change in max. nightly HRV (D1)	0.01 (0 to 0.06)	0.82	1,133	0.37	0.76	
Vaccine × Time point × Headache (D1)	0 (0 to 0.02)	0.79	1,345.3	0.38	0.76	
Change in avg. nightly RR (D1)	0.01 (0 to 0.06)	0.78	1,133.3	0.38	0.76	
Time point × Stomachache (D1)	0 (0 to 0.02)	0.77	1,344.4	0.38	0.76	
Vaccine × Stomachache (D2)	0 (0 to 0.02)	0.73	1,337.4	0.39	0.77	
Time point × Tiredness (D1)	0 (0 to 0.02)	0.72	1,346.7	0.40	0.77	
Vaccine × Tiredness (D1)	0 (0 to 0.02)	0.63	1,347.2	0.43	0.82	
Other allergic reactions (difficulty breathing, swelling of face/throat, rash) (D2)	0 (0 to 0.02)	0.61	1,373.5	0.44	0.82	
Nausea vomiting (D1)	0 (0 to 0.02)	0.51	1,345.8	0.47	0.86	
Vaccine × Time point × Nausea vomiting (D2)	0 (0 to 0.02)	0.51	1,336	0.48	0.86	
Vaccine × Muscle pain (D1)	0 (0 to 0.02)	0.49	1,345.7	0.48	0.86	
Vaccine × Injection site pain, redness or swelling (D2)	0 (0 to 0.02)	0.48	1,337.9	0.49	0.86	
Time point × Symptom count (D1)	0 (0 to 0.02)	0.47	1,345.4	0.49	0.86	
Vaccine × Time point × Symptom count (D1)	0 (0 to 0.02)	0.46	1,345.3	0.50	0.86	
Time point × Pain or swelling in non-injected arm (D2)	0 (0 to 0.02)	0.44	1,339.1	0.51	0.86	
Vaccine × Tiredness (D2)	0 (0 to 0.02)	0.39	1,342.3	0.53	0.90	
Vaccine × Stomachache (D1)	0 (0 to 0.02)	0.33	1,344.8	0.56	0.91	
Vaccine × Injection site pain, redness or swelling (D1)	0 (0 to 0.02)	0.33	1,345.5	0.57	0.91	
Vaccine × Time point × Change in max. nightly skin temp. (D1)	0 (0 to 0.05)	0.29	1,126.6	0.59	0.91	
Vaccine × Time point × Tiredness (D1)	0 (0 to 0.02)	0.29	1,347	0.59	0.91	
Vaccine × Change in avg. nightly RR (D2)	0 (0 to 0.04)	0.27	1,133.3	0.60	0.91	
Pain or swelling in non-injected arm (D2)	0 (0 to 0.02)	0.26	1,340.5	0.61	0.91	
Time point × Headache (D1)	0 (0 to 0.02)	0.26	1,345.7	0.61	0.91	
Vaccine × Time point × Chills (D1)	0 (0 to 0.02)	0.25	1,344.5	0.61	0.91	
Fever (D1)	0 (0 to 0.02)	0.25	1,345.7	0.62	0.91	
Vaccine × Time point × Change in avg. nightly RR (D1)	0 (0 to 0.04)	0.23	1,134.2	0.63	0.91	
Vaccine × Time point × Injection site pain, redness or swelling (D1)	0 (0 to 0.02)	0.23	1,345	0.63	0.91	
Vaccine × Headache (D2)	0 (0 to 0.02)	0.22	1,340.8	0.64	0.91	
Nausea vomiting (D2)	0 (0 to 0.02)	0.22	1,337.4	0.64	0.91	
Time point × Change in max. nightly HRV (D1)	0 (0 to 0.04)	0.22	1,134.2	0.64	0.91	
Pain or swelling in non-injected arm (D1)	0 (0 to 0.02)	0.19	1,345.7	0.66	0.93	
Vaccine × Time point × Headache (D2)	0 (0 to 0.02)	0.18	1,340.1	0.67	0.93	
Time point × Injection site pain, redness or swelling (D1)	0 (0 to 0.02)	0.16	1,345	0.69	0.93	
Vaccine × Time point × Change in min. nightly HR (D2)	0 (0 to 0.04)	0.15	1,134.2	0.70	0.93	
Joint pain (D1)	0 (0 to 0.01)	0.14	1,351.9	0.71	0.93	
Change in max. nightly HRV (D2)	0 (0 to 0.04)	0.14	1,133	0.71	0.93	
Time point × Tiredness (D2)	0 (0 to 0.01)	0.14	1,338.2	0.71	0.93	
Vaccine × Change in avg. nightly RR (D1)	0 (0 to 0.04)	0.12	1,133.2	0.73	0.93	
Stomachache (D2)	0 (0 to 0.01)	0.10	1,337.5	0.75	0.93	
Change in min. nightly HR (D1)	0 (0 to 0.03)	0.10	1,133.4	0.75	0.93	
Vaccine × Time point × Feeling unwell (D1)	0 (0 to 0.01)	0.09	1,348.2	0.76	0.93	
Vaccine × Time point × Joint pain (D1)	0 (0 to 0.01)	0.08	1,356.3	0.78	0.93	

Vaccine × Time point × Tiredness (D2)	0 (0 to 0.01)	0.08	1,341	0.78	0.93	
Vaccine × Time point × Tender or swollen lymph nodes (D2)	0 (0 to 0.01)	0.08	1,343.9	0.78	0.93	
Vaccine × Change in max. nightly HRV (D2)	0 (0 to 0.03)	0.08	1,133.1	0.78	0.93	
Time point × Change in min. nightly HR (D1)	0 (0 to 0.03)	0.07	1,134.5	0.79	0.93	
Vaccine × Time point × Symptom count (D2)	0 (0 to 0.01)	0.07	1,337.4	0.79	0.93	
Time point × Injection site pain, redness or swelling (D2)	0 (0 to 0.01)	0.06	1,336.7	0.81	0.93	
Time point × Feeling unwell (D1)	0 (0 to 0.01)	0.06	1,346.3	0.81	0.93	
Injection site pain, redness or swelling (D1)	0 (0 to 0.01)	0.06	1,345.4	0.81	0.93	
Time point × Tender or swollen lymph nodes (D2)	0 (0 to 0.01)	0.05	1,341.8	0.82	0.93	
Vaccine × Nausea vomiting (D2)	0 (0 to 0.01)	0.05	1,337.5	0.82	0.93	
Time point × Nausea vomiting (D2)	0 (0 to 0.01)	0.04	1,335.8	0.83	0.93	
Vaccine × Time point × Stomachache (D2)	0 (0 to 0.01)	0.04	1,335.9	0.84	0.93	
Vaccine × Time point × Chills (D2)	0 (0 to 0.01)	0.03	1,338.4	0.86	0.94	
Vaccine × Time point × Change in avg. nightly RR (D2)	0 (0 to 0.03)	0.03	1,134.5	0.86	0.94	
Vaccine × Headache (D1)	0 (0 to 0.01)	0.02	1,345.7	0.88	0.95	
Time point × Chills (D1)	0 (0 to 0.01)	0.02	1,344.5	0.89	0.95	
Vaccine × Time point × Fever (D2)	0 (0 to 0.01)	0.02	1,336.9	0.90	0.95	
Vaccine × Time point × Change in max. nightly skin temp. (D2)	0 (0 to 0.02)	0.02	1,127.5	0.90	0.95	
Vaccine × Change in min. nightly HR (D2)	0 (0 to 0.02)	0.01	1,133	0.91	0.95	
Time point × Fever (D2)	0 (0 to 0.01)	0.01	1,336.7	0.92	0.95	
Stomachache (D1)	0 (0 to 0.01)	0.01	1,344.8	0.92	0.95	
Vaccine × Time point × Feeling unwell (D2)	0 (0 to 0.01)	0.01	1,338.9	0.93	0.95	
Feeling unwell (D1)	0 (0 to 0)	0.00	1,346.5	0.95	0.97	
Vaccine × Muscle pain (D2)	0 (0 to 0)	0.00	1,339.2	0.98	0.99	
Time point × Change in max. nightly HRV (D2)	0 (0 to 0)	0.00	1,134.1	0.99	0.99	

**Table S3.** Test statistics and effect sizes (partial eta squared,  $\eta^2$ ) for all hypotheses tested in this manuscript. 18 variables (13 symptoms or symptom categories, 1 symptom count, and 4 biometric variables) measured following receipt of vaccine doses one (for all 3 vaccines) and two (for BNT162b2 and mRNA-1273) were examined as potential predictors of subsequent neutralizing antibodies measured at 1 month and 6 months following completion of the initial vaccination series, via 32 total mixed-effects linear models. Where possible, these models included interaction terms involving the variable under investigation with vaccine, outcome time point, and the three-way interaction between these variables. Statistics were extracted from these models and then all 130 p-values were simultaneously corrected for multiple comparisons using the Benjamini-Hochberg method.

## References

1. N. Wu, K. Joyal-Desmarais, P. A. B. Ribeiro, A. M. Vieira, J. Stojanovic, C. Sanuade, D. Yip, S. L. Bacon, Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. *The Lancet. Respiratory medicine* **11**, 439–452 (2023).
2. Centers for Disease Control and Prevention, COVID Data Tracker (deposited 21 September 2023).
3. A. H. Sinclair, M. K. Taylor, J. S. Weitz, S. J. Beckett, G. R. Samanez-Larkin, Reasons for Receiving or Not Receiving Bivalent COVID-19 Booster Vaccinations Among Adults — United States, November 1–December 10, 2022. *MMWR Morb Mortal Wkly Rep* **72**, 72–75 (2023).
4. E. T. Jacobs, F. M. Cordova-Marks, L. V. Farland, K. C. Ernst, J. G. Andrews, S. Vu, K. M. Heslin, C. Catalfamo, Z. Chen, K. Pogreba-Brown, Understanding low COVID-19 booster uptake among US adults. *Vaccine*. 10.1016/j.vaccine.2023.08.080 (2023).
5. E. A. Hermann, B. Lee, P. P. Balte, V. Xanthakis, B. D. Kirkpatrick, M. Cushman, E. Oelsner, Association of Symptoms After COVID-19 Vaccination With Anti-SARS-CoV-2 Antibody Response in the Framingham Heart Study. *JAMA network open* **5**, e2237908 (2022).
6. A. K. Debes, S. Xiao, E. Colantuoni, E. R. Egbert, P. Caturegli, A. Gadala, A. M. Milstone, Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers. *JAMA internal medicine* **181**, 1660–1662 (2021).
7. N. Tani, Y. Chong, Y. Kurata, K. Gondo, R. Oishi, T. Goto, J. Minami, K. Onozawa, S. Nagano, N. Shimono, H. Ikematsu, H. Kuwano, Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine. *Vaccine* **40**, 2062–2067 (2022).
8. M. J. Choi, J. Y. Heo, Y. B. Seo, Y. K. Yoon, J. W. Sohn, J. Y. Noh, H. J. Cheong, W. J. Kim, J.-Y. Choi, Y. J. Lee, H. W. Lee, S. S. Kim, B. Kim, J. Y. Song, Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study. *Vaccines* **11** (2023).
9. M. Yoshida, Y. Kobashi, T. Kawamura, Y. Shimazu, Y. Nishikawa, F. Omata, H. Saito, C. Yamamoto, T. Zhao, M. Takita, N. Ito, K. Tatsuno, Y. Kaneko, A. Nakayama, T. Kodama, M. Wakui, K. Takahashi, M. Tsubokura, Association of systemic adverse reaction patterns with long-term dynamics of humoral and cellular immunity after coronavirus disease 2019 third vaccination. *Scientific reports* **13**, 9264 (2023).
10. G. Moncunill, R. Aguilar, M. Ribes, N. Ortega, R. Rubio, G. Salmerón, M. J. Molina, M. Vidal, D. Barrios, R. A. Mitchell, A. Jiménez, C. Castellana, P. Hernández-Luis, P. Rodó, S. Méndez, A. Llupia, L. Puyol, N. Rodrigo Melero, C. Carolis, A. Mayor, L. Izquierdo, P. Varela, A. Trilla, A. Vilella, S. Barroso, A. Angulo, P. Engel, M. Tortajada, A. L. García-Basteiro, C. Dobaño, Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. *EBioMedicine* **75**, 103805 (2022).
11. E. G. Levin, Y. Lustig, C. Cohen, R. Fluss, V. Indenbaum, S. Amit, R. Doolman, K. Asraf, E. Mendelson, A. Ziv, C. Rubin, L. Freedman, Y. Kreiss, G. Regev-Yochay, Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. *The New England journal of medicine* **385**, e84 (2021).
12. P. B. Gilbert, D. C. Montefiori, A. B. McDermott, Y. Fong, D. Benkeser, W. Deng, H. Zhou, C. R. Houchens, K. Martins, L. Jayashankar, F. Castellino, B. Flach, B. C. Lin, S. O'Connell, C. McDanal, A. Eaton, M. Sarzotti-Kelsoe, Y. Lu, C. Yu, B. Borate, L. W. P. van der Laan, N. S. Hejazi, C. Huynh,

- J. Miller, H. M. El Sahly, L. R. Baden, M. Baron, L. de La Cruz, C. Gay, S. Kalams, C. F. Kelley, M. P. Andrasik, J. G. Kublin, L. Corey, K. M. Neuzil, L. N. Carpp, R. Pajon, D. Follmann, R. O. Donis, R. A. Koup, Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science (New York, N.Y.)* **375**, 43–50 (2022).
13. T. F. Rogers, F. Zhao, D. Huang, N. Beutler, A. Burns, W.-T. He, O. Limbo, C. Smith, G. Song, J. Woehl, L. Yang, R. K. Abbott, S. Callaghan, E. Garcia, J. Hurtado, M. Parren, L. Peng, S. Ramirez, J. Ricketts, M. J. Ricciardi, S. A. Rawlings, N. C. Wu, M. Yuan, D. M. Smith, D. Nemazee, J. R. Teijaro, J. E. Voss, I. A. Wilson, R. Andrabi, B. Briney, E. Landais, D. Sok, J. G. Jardine, D. R. Burton, Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science (New York, N.Y.)* **369**, 956–963 (2020).
  14. D. Cromer, M. Steain, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, S. J. Kent, J. A. Triccas, D. S. Houry, M. P. Davenport, Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *The Lancet. Microbe* **3**, e52-e61 (2022).
  15. D. S. Houry, D. Cromer, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, K. Subbarao, S. J. Kent, J. A. Triccas, M. P. Davenport, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature medicine* **27**, 1205–1211 (2021).
  16. A. A. Prather, E. G. Dutcher, J. Robinson, J. Lin, E. Blackburn, F. M. Hecht, A. E. Mason, E. Fromer, B. Merino, R. Frazier, J. O'Bryan, S. Drury, E. S. Epel, Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: the BOOST study. *Scientific reports* **13**, 6505 (2023).
  17. J. G. Montoya, A. E. Adams, V. Bonetti, S. Deng, N. A. Link, S. Pertsch, K. Olson, M. Li, E. C. Dillon, D. L. Frosch, Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines. *Microbiology spectrum* **9**, e0116221 (2021).
  18. Y.-A. Kung, S.-Y. Huang, C.-G. Huang, K.-T. Liu, P.-N. Huang, K.-Y. Yu, S.-L. Yang, C.-P. Chen, C.-Y. Cheng, I.-K. Lee, S.-M. Lin, H.-P. Chang, Y.-T. Lin, Y.-C. Liu, G.-W. Chen, S.-R. Shih, Factors influencing neutralizing antibody titers elicited by coronavirus disease 2019 vaccines. *Microbes and infection* **25**, 105044 (2023).
  19. K. D. Dieckhaus, M.-J. Kim, J.-B. Shen, T. S. Liang, M. J. Kleinberg, K. M. Siedlarz, D. B. Banach, M. L. Metersky, R. P. Fuller, E. M. Mortensen, B. T. Liang, SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination. *Vaccines* **11** (2023).
  20. A. Cheng, M.-J. Hsieh, S.-Y. Chang, S.-M. Ieong, C.-Y. Cheng, W.-H. Sheng, S.-C. Chang, Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations. *Journal of the Formosan Medical Association = Taiwan yi zhi* **122**, 384–392 (2023).
  21. A. E. Mason, P. Kasl, W. Hartogensis, J. L. Natale, S. Dilchert, S. Dasgupta, S. Purawat, A. Chowdhary, C. Anglo, D. Veasna, L. S. Pandya, L. M. Fox, K. Y. Puldon, J. G. Prather, A. Gupta, I. Altintas, B. L. Smarr, F. M. Hecht, Metrics from Wearable Devices as Candidate Predictors of Antibody Response Following Vaccination against COVID-19: Data from the Second TemPredict Study. *Vaccines* **10** (2022).
  22. KFF, *KFF Health Tracking Poll: KFF COVID-19 Vaccine Monitor* (2023).
  23. D. Zhong, S. Xiao, A. K. Debes, E. R. Egbert, P. Caturegli, E. Colantuoni, A. M. Milstone, Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. *JAMA* **326**, 2524–2526 (2021).

24. C. Menni, K. Klaser, A. May, L. Polidori, J. Capdevila, P. Louca, C. H. Sudre, L. H. Nguyen, D. A. Drew, J. Merino, C. Hu, S. Selvachandran, M. Antonelli, B. Murray, L. S. Canas, E. Molteni, M. S. Graham, M. Modat, A. D. Joshi, M. Mangino, A. Hammers, A. L. Goodman, A. T. Chan, J. Wolf, C. J. Steves, A. M. Valdes, S. Ourselin, T. D. Spector, Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. *The Lancet. Infectious diseases* **21**, 939–949 (2021).
25. E. Hodcroft, CoVariants.
26. A. Sette, J. Sidney, S. Crotty, T Cell Responses to SARS-CoV-2. *Annual review of immunology* **41**, 343–373 (2023).
27. A. Bertoletti, N. Le Bert, A. T. Tan, SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. *Immunity* **55**, 1764–1778 (2022).
28. H. Kinnunen, A. Rantanen, T. Kenttä, H. Koskimäki, Feasible assessment of recovery and cardiovascular health: accuracy of nocturnal HR and HRV assessed via ring PPG in comparison to medical grade ECG. *Physiological measurement* **41**, 04NT01 (2020).
29. A. Maijala, H. Kinnunen, H. Koskimäki, T. Jämsä, M. Kangas, Nocturnal finger skin temperature in menstrual cycle tracking: ambulatory pilot study using a wearable Oura ring. *BMC women's health* **19**, 150 (2019).
30. M. Shilaih, B. M. Goodale, L. Falco, F. Kübler, V. de Clerck, B. Leeners, Modern fertility awareness methods: wrist wearables capture the changes in temperature associated with the menstrual cycle. *Bioscience reports* **38** (2018).
31. T. Y. Zhu, M. Rothenbühler, G. Hamvas, A. Hofmann, J. Welter, M. Kahr, N. Kimmich, M. Shilaih, B. Leeners, The Accuracy of Wrist Skin Temperature in Detecting Ovulation Compared to Basal Body Temperature: Prospective Comparative Diagnostic Accuracy Study. *Journal of medical Internet research* **23**, e20710 (2021).
32. H. G. Rosenblum, J. Gee, R. Liu, P. L. Marquez, B. Zhang, P. Strid, W. E. Abara, M. M. McNeil, T. R. Myers, A. M. Hause, J. R. Su, L. E. Markowitz, T. T. Shimabukuro, D. K. Shay, Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. *The Lancet. Infectious diseases* **22**, 802–812 (2022).
33. Ø. Langsrud, ANOVA for unbalanced data: Use Type II instead of Type III sums of squares. *Statistics and Computing* **13**, 163–167 (2003).